Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
Gilead files Truvada follow-up Descovy for PrEPGilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending Share XGilead files Truvada follow-up Descovy for PrEPhttps://pharmaphorum.com/news/gilead-files-truvada-follow-up-descovy-for-prep/
